台灣臨床試驗主持人資料庫|TPIDB

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

Condition/Disease

Squamous Cell Head and Neck Cancer
Test Drug

SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新

Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄

Taipei Medical University Hospital

Division of Hematology & Oncology

2018-03-01 - 2020-02-29

Phase II

A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects with Hair Loss

Condition/Disease

Hair Loss
Test Drug

ENERGI-F701

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

陳志強

Taipei Veterans General Hospital

Division of Dermatology

2015-09-07 - 2020-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Condition/Disease

Advanced or Metastatic Soft Tissue Sarcoma
Test Drug

Olaratumab (LY3012207)

Participate Sites
3Sites

Terminated3Sites

顏厥全

Taipei Veterans General Hospital

Division of General Internal Medicine

2015-08-14 - 2024-05-01

Phase III

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

Ramucirumab

Participate Sites
10Sites

Recruiting5Sites

Terminated4Sites

羅永鴻

Taipei Veterans General Hospital

夏德椿

China Medical University Hospital-Taipei

未分科

2018-07-30 - 2022-08-13

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-07-01 - 2019-12-24

Phase III

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER

Condition/Disease

Epithelial Ovarian Cancer
Test Drug

MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
7Sites

Terminated7Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-12-26 - 2021-04-08

Phase III

A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Condition/Disease

Squamous Cell Carcinoma of the Head and Neck
Test Drug

MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
8Sites

Terminated7Sites

張牧新

Taipei Veterans General Hospital

2017-02-01 - 2027-02-01

Phase III

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Condition/Disease

Hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Test Drug

Ibrance

Participate Sites
6Sites

Terminated5Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

2018-04-13 - 2022-04-13

Phase II

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Condition/Disease

Advanced Non-Small Cell Lung Carcinoma
Test Drug

REGN2810

Participate Sites
5Sites

Terminated5Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-01-31 - 2026-02-08

Phase III

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

Condition/Disease

Acute Myeloid Leukemia, AML
Test Drug

Glasdegib (PF-04449913)

Participate Sites
5Sites

Recruiting5Sites

高志平

Taipei Veterans General Hospital

Division of Hematology & Oncology

Search Result

List